Singapore markets close in 4 hours 47 minutes

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

Toronto - Toronto Real-time price. Currency in CAD
Add to watchlist
4.9900+0.0900 (+1.84%)
At close: 03:54PM EST
Full screen
Previous close4.9000
Open5.0000
Bid4.9800 x N/A
Ask5.0000 x N/A
Day's range4.9200 - 5.0000
52-week range0.8000 - 5.2300
Volume26,360
Avg. volume25,031
Market cap106.752M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.2720
Earnings date07 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.35
  • CNW Group

    Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee Osteoarthritis

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has completed enrollment, randomization and dosing of the last patient, in its Phase 2 trial that is evaluating the efficacy and safety of EP-104 for the treatment of osteoarthritis ("OA") of the knee.

  • CNW Group

    Eupraxia Pharmaceuticals Reports Third Quarter 2022 Financial Results

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the third quarter ended September 30, 2022. All amounts are expressed in Canadian dollars unless otherwise indicated.

  • CNW Group

    Eupraxia Pharmaceuticals Appoints Chief Business Officer

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has appointed Paul Brennan to the role of Chief Business Officer ("CBO").